ADMA Biologics Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Roundhill NVDA WeeklyPay ETF trades at $38.32. The key difference: Roundhill NVDA WeeklyPay ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | NVDW | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $20.38 | $52.59 |
52-Week Low | $7.60 | $31.88 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
NVDW trades at $38.58, up 3.35% today with a bullish technical signal supported by moving averages. The stock shows strong momentum with key indicators suggesting mild overbought conditions. Recent dividend activity indicates consistent shareholder returns, though financial ratios remain undisclosed pending updated filings.
Outlook remains positive given technical strength and dividend consistency, but limited fundamental data requires caution. Key risks include dependency on underlying NVDA performance and payout volatility. Investors should await comprehensive financial disclosures for full valuation assessment.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →